Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

Yıl 2014, Cilt: 31 Sayı: 1, 31 - 36, 05.06.2014

Öz

Exposure to John Cunningham Virus (JCV) has been associated with Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) patients under specific treatments. In order to assess the identifiable risks of Turkish relapsing-remitting multiple sclerosis (RRMS) patients, the seroprevalence rate of JCV antibodies was investigated and compared with demographic and therapy related factors. Serum samples were collected from 308 RRMS patients at 24 centers, and tested by STRATIFY JCV assay for the presence of anti-JCV antibodies. Also, demographic, disease and treatment data were collected at the same time and were used for analysis of associations with seropositivity. The prevalence of anti-JCV antibodies was observed to be 68.2%, which is higher than most countries. There was a trend in terms of higher seroprevalence of antibodies in older patients, and male patients. There was no association with previous
natalizumab use, but there was a significantly higher seroprevalence in patients who used immunosuppressant therapies (p<0.05). JCV prevalence rate is observed to be
high in Turkish MS patients, therefore it would be beneficial to use this marker as a risk stratification tool in clinical decision making.

Anahtar Kelimeler

John Cunningham Virus, Multiple Sclerosis, Natalizumab, Turkey

Kaynakça

Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.
Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.
Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.
Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).

Toplam 4 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	İngilizce
Konular	Sağlık Kurumları Yönetimi
Bölüm	Basic Medical Sciences
Yazarlar	Mefkure Eraksoy Bu kişi benim Kadriye Agan Bu kişi benim Fikri Ak Bu kişi benim Omer Anlar Bu kişi benim Belgin Balcı Bu kişi benim Cavit Boz Bu kişi benim Yahya Celık Bu kişi benim Seref Demırkaya Bu kişi benim Husnu Efendı Bu kişi benim Muhtesem Gecızlıoglu Bu kişi benim Dilek Gunal Bu kişi benim Hulya Aydın Gungor Bu kişi benim Nihal Isık Bu kişi benim Egemen Idılman Bu kişi benim Rana Karabudak Bu kişi benim Aslı Kurne Bu kişi benim Munife Neyal Bu kişi benim Serkan Ozakbas Bu kişi benim Ozgul Ekmekcı Ozbay Bu kişi benim Cemal Ozcan Bu kişi benim Nese Oztekın Bu kişi benim Musa Ozturk Bu kişi benim Sabahattin Saıp Bu kişi benim Aksel Sıva Bu kişi benim Aysun Soysal Bu kişi benim Ozlem Taskapılıoglu Bu kişi benim Murat Terzı Bu kişi benim Omer Turan Bu kişi benim Recai Turkoglu Bu kişi benim Nezih Yucemen Bu kişi benim Ayse Yuceyar Bu kişi benim Yasar Zorlu Bu kişi benim Cunay Ulku Bu kişi benim Huseyin Dıb Bu kişi benim Deniz Uren Bu kişi benim
Yayımlanma Tarihi	5 Haziran 2014
Gönderilme Tarihi	16 Aralık 2013
Yayımlandığı Sayı	Yıl 2014 Cilt: 31 Sayı: 1

Kaynak Göster

APA	Eraksoy, M., Agan, K., Ak, F., Anlar, O., vd. (2014). Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Journal of Experimental and Clinical Medicine, 31(1), 31-36.
AMA	Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. Haziran 2014;31(1):31-36.
Chicago	Eraksoy, Mefkure, Kadriye Agan, Fikri Ak, Omer Anlar, Belgin Balcı, Cavit Boz, Yahya Celık, Seref Demırkaya, Husnu Efendı, Muhtesem Gecızlıoglu, Dilek Gunal, Hulya Aydın Gungor, Nihal Isık, Egemen Idılman, Rana Karabudak, Aslı Kurne, Munife Neyal, Serkan Ozakbas, Ozgul Ekmekcı Ozbay, Cemal Ozcan, Nese Oztekın, Musa Ozturk, Sabahattin Saıp, Aksel Sıva, Aysun Soysal, Ozlem Taskapılıoglu, Murat Terzı, Omer Turan, Recai Turkoglu, Nezih Yucemen, Ayse Yuceyar, Yasar Zorlu, Cunay Ulku, Huseyin Dıb, ve Deniz Uren. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Journal of Experimental and Clinical Medicine 31, sy. 1 (Haziran 2014): 31-36.
EndNote	Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D (01 Haziran 2014) Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Journal of Experimental and Clinical Medicine 31 1 31–36.
IEEE	M. Eraksoy, “Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey”, J. Exp. Clin. Med., c. 31, sy. 1, ss. 31–36, 2014.
ISNAD	Eraksoy, Mefkure vd. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Journal of Experimental and Clinical Medicine 31/1 (Haziran 2014), 31-36.
JAMA	Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31:31–36.
MLA	Eraksoy, Mefkure vd. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Journal of Experimental and Clinical Medicine, c. 31, sy. 1, 2014, ss. 31-36.
Vancouver	Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31(1):31-6.

Kapak Resmi İndir

Makale Dosyaları

Tam Metin

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.